14 July 2025

Physiomics plc

("Physiomics" or the "Company")

Trading Update

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that its Total Income and Loss after Tax will exceed market expectations for the financial year ending 30 June 2025 (FY25).

Based on unaudited end of year accounts for FY25, the Company is projecting to finish the year with a Total Income of £834k and Loss after Tax of £419k, both metrics being ahead of expectations for FY25. When compared to the year ended 30 June 2024 (FY24), these unaudited numbers would represent an increase in Total Income of approximately 46% and a reduction in Loss after Tax of approximately 31%, reflecting the positive growth trajectory of the business and effective cost management.

The Company continues to build its pipeline with the average total value of contract wins over FY24 and FY25 reaching a record high of over £1m per year, a 63% increase on the yearly average over the previous five years. The Company started the current financial year ending 30 June 2026 (FY26) with approx. £593k of contracted revenue that is projected to be recognised within the year. This compares to approximately £500k worth of contracts carried forward from the year ended 30 June 2023 (FY23) into FY24, an 18.6% year-on-year increase. We are therefore confident that further revenue growth can be achieved in FY26.

In addition, the Company expects that £60k worth of Grant Income will be recognised in FY26.

The Company is also generating momentum across its key growth initiatives:

-    Biometrics service line: June 2025 announcement of the Company's first two Biometrics contracts worth £111k and recruitment of Head of Biometrics, Jesse Thissen

-    Diversification of client base: 31% of all contract awards in FY25 were from new clients, compared to 17% over the prior six years.

-    Expansion into new therapeutic areas: 50% of projects delivered in FY25 were in therapeutic areas outside oncology, compared to an average of 5% over the previous three years

-    Personalised Medicine - Recently announced expanded relationship with DoseMe Inc and Implementation of the Company's Dosing software onto the DoseMeRx Platform, and progress of the PREDICT-ONC trial.

Dr Peter Sargent, CEO of Physiomics, commented:

"I am thrilled that the changes we've made here at Physiomics are starting to have a positive effect on the Company's performance. Not only will we exceed expectations for FY25, but we've started FY26 with record levels of contracted revenue yet to be recognised and are generating significant momentum across our key growth initiatives."

For more information about Physiomics and its services, please visit www.physiomics.co.uk.

Enquiries:

Physiomics plc

Dr Peter Sargent, CEO

+44 (0)1235 841575

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018 (as amended).

Notes to Editor

About Physiomics

Physiomics plc combines expertise across Modelling & Simulation, Biostatistics, Data Science and Bioinformatics, together with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to help derive insight from all relevant and often disparate data in order to de-risk decision making and optimise research design across discovery, pre-clinical and clinical studies. Through use of cutting-edge computational tools, bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 commercial projects, with over 125 targets and drugs modelled. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.